Morse Asset Management Inc Purchases 942 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Morse Asset Management Inc raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 282.0% in the third quarter, HoldingsChannel reports. The fund owned 1,276 shares of the biopharmaceutical company’s stock after purchasing an additional 942 shares during the quarter. Morse Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $968,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Orbimed Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $11,358,000. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $6,327,000. Compass Financial Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4,526.2% during the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after buying an additional 2,942 shares during the last quarter. Finally, Oxbow Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $3,342,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a report on Monday, November 2nd. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. Finally, Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a research note on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $898.97.

View Our Latest Stock Report on Regeneron Pharmaceuticals

Insider Buying and Selling

In related news, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares in the company, valued at approximately $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 7,439 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 27,028 shares of company stock valued at $25,025,950 over the last quarter. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $955.47 on Monday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The company has a 50-day simple moving average of $816.17 and a two-hundred day simple moving average of $747.36. The company has a market capitalization of $98.84 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same quarter last year, the business posted $11.83 EPS. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.